AXIM Biotechnologies (OTCMKTS:AXIM – Get Rating) is one of 376 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare AXIM Biotechnologies to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.
Analyst Ratings
This is a summary of current recommendations and price targets for AXIM Biotechnologies and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AXIM Biotechnologies | 0 | 0 | 0 | 0 | N/A |
| AXIM Biotechnologies Competitors | 494 | 1603 | 4626 | 55 | 2.63 |
As a group, “Biotechnology” companies have a potential upside of 80.95%. Given AXIM Biotechnologies’ rivals higher probable upside, analysts clearly believe AXIM Biotechnologies has less favorable growth aspects than its rivals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| AXIM Biotechnologies | N/A | N/A | N/A |
| AXIM Biotechnologies Competitors | -636.54% | -58.71% | -17.44% |
Institutional & Insider Ownership
25.9% of shares of all “Biotechnology” companies are held by institutional investors. 25.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares AXIM Biotechnologies and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| AXIM Biotechnologies | N/A | N/A | -4.37 |
| AXIM Biotechnologies Competitors | $118.59 million | -$13.54 million | 22.21 |
AXIM Biotechnologies’ rivals have higher revenue, but lower earnings than AXIM Biotechnologies. AXIM Biotechnologies is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Summary
AXIM Biotechnologies rivals beat AXIM Biotechnologies on 5 of the 8 factors compared.
AXIM Biotechnologies Company Profile
AXIM Biotechnologies, Inc. operates as a biotechnology company, which engages in the development of diagnostic healthcare solutions. Its product categories include Eye Health, SARS-CoV-2, and fentanyl neutralizing antibody test. The company was founded on November 18, 2010 and is headquartered in San Diego, CA.
Receive News & Ratings for AXIM Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AXIM Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
